Compare VanEck Junior Gold Miners (GDXJ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Recursion Pharmaceuticals Inc — how do they compare? VanEck Junior Gold Miners trades at $119.01, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: VanEck Junior Gold Miners is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GDXJ | RXRX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $6.79 |
52-Week Low | $71.22 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ trades at $120.71, up 1.62% today, with a bullish technical trend from moving averages but overbought signals from RSI levels. The ETF faces mixed sentiment, with recent news highlighting institutional selling by Amundi and underperformance versus peers in 2026. Support lies near $116, with resistance at $121.
The outlook is cautious due to high RSI readings and bearish oscillators, suggesting potential near-term pullbacks. Risks include Federal Reserve policy impacts on gold prices and competitive pressures from larger miner ETFs. Institutional activity shows reduced positions, indicating tempered confidence.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
